Vaso Corporation

瓦索公司

137 Commercial Street

商业街137号

Plainview, New York 11803

纽约州普莱恩维尤 11803

Tel: (516) 997-4600 Fax: (516) 997-2299

电话：(516) 997-4600 传真：(516) 997-2299

Investor Contact:

投资者联系：

Jonathan Newton

乔纳森·牛顿

Investor Relations

投资者关系

Phone: 516-997-4600

电话：516-997-4600

Email:

电子邮件：

jnewton@vasocorporation.com

jnewton@vasocorporation.com

PLAINVIEW, N.Y., Aug. 03, 2026 (GLOBE NEWSWIRE) --

纽约州普莱恩维尤，2026年8月3日（环球新闻社）——

Vaso Corporation (“Vaso”) (OTCQX: VASO), a leading MedTech company with businesses in healthcare professional sales services and proprietary medical products, announced today that it completed the sale of NetWolves Network Services LLC (“NetWolves”) to COEO Solutions, LLC (“COEO”) on July 31, 2026. The transaction was structured as a sale of equity..

Vaso Corporation（“Vaso”）（OTCQX: VASO）是一家领先的医疗科技公司，业务涵盖医疗健康专业服务销售和自有医疗产品。该公司今日宣布，已于2026年7月31日完成向COEO Solutions, LLC（“COEO”）出售NetWolves Network Services LLC（“NetWolves”）的交易。该交易以股权出售的形式进行。

NetWolves had operated as Vaso’s managed network services and connectivity business. The company provided managed network services and connectivity solutions, including network design, redundancy, application device management, real-time network monitoring, reporting and support systems. Its service offerings included connectivity, security, managed services, cloud and professional services, as well as single-source billing for customers..

NetWolves 曾作为 Vaso 的托管网络服务和连接业务运营。该公司提供托管网络服务和连接解决方案，包括网络设计、冗余、应用设备管理、实时网络监控、报告和支持系统。其服务产品包括连接、安全、托管服务、云和专业服务，以及为客户提供单一来源账单。

The sale follows Vaso’s review of its long-term business strategy and supports the Company’s continued focus on its healthcare businesses through VasoHealthcare and VasoMedical. The transaction allows Vaso to sharpen its focus on its core healthcare operations while positioning NetWolves for its next phase of growth under new ownership..

此次出售是在Vaso审查其长期业务战略之后进行的，有助于公司通过VasoHealthcare和VasoMedical继续专注于其医疗健康业务。该交易使Vaso能够更加聚焦于其核心医疗健康运营，同时为NetWolves在新所有权下进入下一轮增长阶段奠定基础。

COEO is a provider of managed network and cloud communications solutions serving small and mid-sized, multi-location enterprises.

COEO 是一家为中小型多地点企业提供托管网络和云通信解决方案的服务商。

“The sale of NetWolves, together with the sale of VasoHealthcare IT Corp. in November 2025, completes Vaso’s divestiture of its IT segment under VasoTechnology, Inc.,” said Dr. Jun Ma, President and Chief Executive Officer of Vaso Corporation. “This transaction allows Vaso to focus its resources on the continued development of its healthcare businesses through VasoHealthcare and VasoMedical.

“NetWolves的出售，连同2025年11月VasoHealthcare IT Corp.的出售，标志着Vaso通过VasoTechnology, Inc.对其IT业务部门的剥离工作圆满完成。”Vaso Corporation总裁兼首席执行官马军博士表示。“此次交易使Vaso能够集中资源，通过VasoHealthcare和VasoMedical持续推进其医疗健康业务的发展。”

We appreciate the contributions of the NetWolves team and their service to customers over the years.”.

我们感谢 NetWolves 团队多年来的贡献及其为客户提供的服务。

VasoHealthcare and VasoMedical will continue operating as they do today, focused on serving customers, supporting partners and executing Vaso’s growth strategy. Vaso expects to support an orderly transition for NetWolves customers, employees, vendors and business partners.

VasoHealthcare 和 VasoMedical 将继续保持目前的运营模式，专注于服务客户、支持合作伙伴并执行 Vaso 的增长战略。Vaso 预计将为 NetWolves 的客户、员工、供应商及业务合作伙伴提供有序过渡的支持。

The purchase price for NetWolves was $14,500,000.00 in cash, subject to customary post-closing adjustments based on net working capital, closing cash, closing indebtedness, unpaid seller expenses and escrows, as more fully described in the Purchase Agreement. Additional information regarding the transaction is available in Vaso Corporation’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 31, 2026..

NetWolves的收购价格为14,500,000.00美元现金，须根据净营运资本、期末现金、期末债务、未付卖方费用及托管资金进行惯常的交割后调整，具体详见《购买协议》。有关该交易的更多信息，请参阅Vaso Corporation于2026年7月31日向美国证券交易委员会提交的8-K表格当前报告。

Advisors

顾问

The DAK Group, Ltd. served as financial advisor to Vaso Corporation in connection with the transaction, and Barley Snyder LLP served as legal counsel to Vaso Corporation.

DAK集团有限公司担任了Vaso公司在此次交易中的财务顾问，Barley Snyder LLP律师事务所则担任了Vaso公司的法律顾问。

About Vaso

关于Vaso

Vaso Corporation (OTCQX: VASO), headquartered in Plainview, New York, is a diversified healthcare-focused organization operating through VasoHealthcare and VasoMedical. VasoHealthcare is the professional sales service arm for GE HealthCare’s diagnostic imaging and ultrasound products. VasoMedical designs and manufactures proprietary medical devices, including Biox series devices, and develops and operates the ARCS cloud-based SaaS platform.

瓦索公司（OTCQX：VASO）总部位于纽约州普莱恩维尤，是一家多元化的医疗健康领域企业，通过瓦索医疗（VasoHealthcare）和瓦索医学（VasoMedical）两大业务板块开展运营。瓦索医疗是通用电气医疗（GE HealthCare）诊断影像和超声产品的专业销售服务部门。瓦索医学则设计并制造自有品牌医疗器械，包括Biox系列设备，同时开发并运营基于云端的SaaS平台ARCS。

For additional information, please visit .

如需更多信息，请访问。

www.vasocorporation.com

www.vasocorporation.com

or contact

或联系

info@vasocorporation.com

info@vasocorporation.com

.

。

Forward-Looking Statements

前瞻性陈述

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “may,” “optimistic,” “plans,” “potential,” “looking forward,” “intends,” and similar expressions, as they relate to the Company or its management, identify forward-looking statements.

除本新闻稿中包含的历史信息外，所讨论的事项均属于涉及风险和不确定性的前瞻性陈述。在本新闻稿中，“预期”、“相信”、“可能”、“估计”、“期望”、“或许”、“乐观”、“计划”、“潜在”、“展望”、“打算”等词语以及类似表述，若与公司或其管理层相关，则用于识别前瞻性陈述。

Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management..

此类前瞻性陈述基于公司管理层的信念，以及管理层所作出的假设和目前掌握的信息。

Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of changes taking place in information technology and healthcare; continuation of the GE HealthCare agreement; the impact of competitive technology and products and their pricing; medical insurance reimbursement policies; manufacturing or supplier problems; unforeseen difficulties and delays in product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; risks associated with business transitions and post-closing operations; and the risk factors reported from time to time in the Company’s SEC reports.

可能导致实际结果出现重大差异的因素包括以下各项：商业和经济状况的影响；信息技术和医疗保健领域变化的影响；GE HealthCare协议的持续履行；竞争性技术、产品及其定价的影响；医疗保险报销政策；制造或供应商问题；产品开发计划中不可预见的困难和延误；美国及海外监管机构和第三方付款方的行动；与业务过渡及交割后运营相关的风险；以及公司不时在美国证券交易委员会（SEC）报告中披露的风险因素。

The Company undertakes no obligation to update forward-looking statements as a result of future events or developments..

本公司不承担因未来事件或发展而更新前瞻性陈述的义务。